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Abstract: Tolvaptan is the first FDA-approved oral V2 receptor antagonist for the treatment 
of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free 
water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic 
hormone secretion. Tolvaptan inhibits the binding of arginine vasopressin to the V2 receptors 
on the collecting ducts of the kidneys resulting in aquaresis, the electrolytes sparing excretion 
of water. This article reviews the accumulated experience with tolvaptan and all the major 
clinical trials that were conducted to study its safety and efficacy and concludes by summarizing 
clinicians’ views of its current application in clinical practice.
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Introduction
Hyponatremia is the most common electrolyte abnormality seen in hospital-
ized patients1 and is associated with increased morbidity that includes cognitive 
impairment,2 falls,2 fractures, and osteoporosis;3–5 longer hospital stay; and increased 
mortality.1,6–8 It is traditionally defined as serum Na+ #135 mEq/L.1 However, serum 
Na+ concentration #138 mEq/L was found to be associated with worsened outcome,6–9 
so hyponatremia should be redefined as serum Na+ concentration #138 mEq/L.10
Since Na+ is the major determinant of plasma osmolality, hyponatremia is 
usually associated with hyposmolality. It may present as euvolemic hyponatremia 
as seen in the syndrome of inappropriate antidiuretic hormone secretion (SIADH), 
or hypervolemic hyponatremia in edema-forming conditions such as heart failure 
(HF) or cirrhosis. Hypovolemic hyponatremia is due to conditions promoting renal 
or extra-renal Na+ loss.1
The clinical manifestations of hyponatremia include malaise, headache, nausea, 
vomiting, lethargy, confusion, stupor, seizure, and coma, depending on the severity of 
hyponatremia and the rapidity of its development.1 However, hyponatramic patients 
frequently have subtle symptoms, and are often perceived as asymptomatic, which 
explains why hyponatremia is frequently undiagnosed and untreated.11
Given the limitations to the traditional treatment of hyponatremia, fluid restriction 
with or without the use of lithium, demeclocycline, and urea, the introduction of 
vasopressin antagonists with their ability to induce aquaresis, the electrolyte free 
excretion of water, has provided an attractive option to the treatment of hyponatremia 
by directly opposing the action of arginine vasopressin (AVP).International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Arginine vasopressin  
and its receptors
AVP is a peptide hormone composed of 9 amino acids that 
plays a major role in preserving water balance, osmolality, 
and blood volume. It is synthesized in the hypothalamus, 
stored in the posterior pituitary gland, and then released as 
needed into the hypophyseal portal vein.11
Under normal conditions, the release of AVP is con-
trolled primarily by osmolality. Osmoreceptors located in 
several areas of the brain are very sensitive to changes in 
serum   osmolality. A rise in serum osmolality by 1% will 
stimulate the release of AVP, and in sequence increase 
water   re-absorption at the renal tubule, causing water 
retention.12,13
Change in the circulating blood volume is the second 
mechanism by which AVP is stimulated. The baro-receptors 
in the carotid sinus and stretch receptors in the wall of the 
great veins, atria, and pulmonary trunk are sensitive to 
changes in the volume status (eg, volume depletion and/or 
hypotension).14,15 As low as 5% to 10% decrease in blood 
volume will lead to AVP release and subsequent water 
retention to restore the intravascular volume.14,15 This occurs 
in conditions characterized by arterial under-filling, such 
as HF due to low cardiac output and liver cirrhosis due to 
vasodilatation.
The release of AVP is accounted for predominantly by 
the above 2 mechanisms, but its secretion is also affected by 
other factors including endogenous angiotensin II, stress, 
and pain.15,16
AVP receptors are G protein-coupled receptors that medi-
ate cardiovascular and renal functions. There are 3 subtypes 
(V1A, V2, and V1B). Table 1 summarizes the location and 
functions of the different receptors.17–20
Arginine vasopressin antagonists
The first non-peptide AVP antagonist was discovered in 
1992 and subsequently several had been developed.21 By 
binding to the V2 receptors, they prevent the cascade leading 
to the insertion of aquaporin 2 (AQP-2) water channels 
into the luminal membrane of the principal cells and water 
reabsorption.19 Conivaptan is the first intravenous dual 
V1A/V2 receptor antagonist approved by the US Food and 
Drug Administration (FDA) and tolvaptan is the first oral 
antagonist.
Tolvaptan
Tolvaptan (OPC-41061) is a potent, orally active, non-  peptide 
V2 receptor antagonist. It was the first oral AVP receptor 
antagonist to be approved (in May 2009) by the FDA for 
the treatment of hypervolemic or euvolemic hyponatremia 
(associated with HF, cirrhosis, or SIADH) with either a serum 
Na+ concentration ,125 mEq/L or less marked hyponatremia 
that is symptomatic and resistant to fluid restriction.20 It is 
produced by Otsuka Pharmaceutical Co Ltd, Rockville, MD 
and is available under the brand name Samsca®.22
Pharmacokinetics  
and pharmacodynamics
Tolvaptan is a selective V2 receptor antagonist with an affin-
ity for the V2 receptor that is 1.8 times that of native AVP. 
Tolvaptan’s affinity for the V2 receptor is 29 times greater 
than its affinity for the V1A receptor.23
The pharmacokinetics of tolvaptan have been studied in 
healthy subjects at different single or multiple daily doses 
of up to 480 mg. For single oral doses ranging from 60 to 
480 mg, the area under the curve (AUC) increases propor-
tionally with dose. The apparent clearance was independent 
of the dose at clinically used doses.24
The time to peak concentration (Tmax) was observed ≈2 
to 4 hours post-dose. The absolute bioavailability of tolvap-
tan is unknown, but at least 40% of the dose is absorbed as 
tolvaptan or metabolites, and its absorption is not affected 
by food intake. Tolvaptan is highly bound to plasma protein 
(99%), and its volume of distribution is about 3 L/kg in 
healthy   subjects, and slightly higher in patients with HF.25 The 
  estimated t1/2 of tolvaptan is slightly shorter than 12 hours.20
From 0 to 12 hours post-dose, mean urine volume, 
free water clearance, and urine osmolality were similar for 
Table 1 Arginine vasopressin receptors18–21
Receptor Location Function
v1A vascular smooth muscle cells, hepatocytes,  
platelets, uterus, renal, adrenal, and brain cells.
vasoconstriction, glycogenolysis, platelet aggregation, and myocytes 
hypertrophy.
v1B Anterior pituitary gland Mediate the release of adrenocorticotropin hormone and endorphines.
v2 Collecting ducts of the kidney. Mediate free water absorption by mobilizing intracellular vesicles of aquaporin-2 
(AQP2) to the apical plasma membrane of the collecting duct cells, causing an 
increase in water permeability and antidiuretic effect.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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all doses, but 12 to 24 hours post dose, the mean free water 
clearance generally increased with increasing dose, and urine 
osmolality decreased with increasing dose.24   Throughout 
the 0- to 24-hour period, increases were seen in mean 
serum Na+ concentration (∼4–6 mEq/L), plasma   osmolality 
(∼8 mOsm/kg), and free water clearance (∼6 mL/min); 
while mean urine concentration of Na+ and potassium (K+) 
were decreased to less than 20 mEq/L with no change in the 
serum K+ concentration.24 Co-administration of tolvaptan and 
furosemide produced a higher increase in urine volume and 
free water clearance, a greater decrease in urinary   osmolality, 
and no further increase in rennin activity and aldosterone 
concentration, compared with furosemide alone.26
Drug formulation and dosing
Tolvaptan is present in tablet form with different shapes 
according to the dosage. It is available in 15, 30, and 60 mg 
strengths. It should be stored at controlled room temperature 
between 59° and 86°F (15–30°C) and can be administered 
with or without food.22 The recommended starting dose is 
15 mg/day, which may be increased at intervals $24 hour 
to 30 mg/day, and to a maximum of 60 mg/day.
Close monitoring of the serum Na+ and volume status is 
a necessity to avoid complication from rapid correction of 
hyponatremia (eg, osmotic demyelination). Fluid restriction 
should be avoided during the first 24 hours of therapy, and 
patients should be advised to continue fluid ingestion in 
response to thirst.
Metabolism and drug interaction
Tolvaptan is metabolized mainly in the liver, primarily by 
cytochrome P450 (CYP 3A), and ,1% is excreted unchanged 
in the urine.24 The co-administration of tolvaptan with keto-
conazole or other strong CYP 3A inhibitor (eg, clarithromycin, 
itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir, 
and nefazodone) decreases the total clearance of tolvaptan and 
increases tolvaptan concentrations. The co-administration of 
grapefruit juice and tolvaptan results in a 1.8-fold increase in 
tolvaptan exposure.27 On the other hand, the co-administrations 
of tolvaptan with rifampin or other CYP 3A inducers (eg, rifab-
utin, rifapentin, barbiturates, phenytoin, carbamazepine, and 
St John’s Wort) results in increased metabolism of   tolvaptan, 
which decreases its effects.20,28
Tolvaptan shows no significant pharmacokinetic 
interactions with amiodarone, warfarin, furosemide, or 
hydrochlorothiazide.29,30 Also, there was no clinically relevant 
change in lovastatin or digoxin effects when co-administered 
with tolvaptan.28,31
Contraindications, precautions,  
and side effects
Tolvaptan is contraindicated with the use of a strong CYP 3A 
inhibitor due to drug interaction. It is also contraindicated 
in hypovolemic hyponatremia because it might precipitate 
hypotension and renal failure. It should not be administered 
in anuric patients due to expected lack of clinical benefit. 
Patients who are unable to sense or appropriately respond 
to thirst stimulation should not take tolvaptan because this 
increases the risk of rapid correction of serum Na+.
Tolvaptan use in pregnancy is category C, so it should be 
used only if the potential benefit justifies the potential fetal 
risk, and it is excreted into the milk of lactating rats, so that 
mothers should discontinue nursing or stop tolvaptan.
The FDA has restricted the initiation and re-initiation of 
tolvaptan to the hospital setting, where the serum Na+ can be 
monitored closely. Since rapid correction of hyponatremia 
(.12 mEq/L/day) may cause osmotic demyelination result-
ing in severe neurological complications and possible death, 
caution should be advised with concomitant use of tolvaptan 
and hypertonic saline.
The most common adverse reactions (incidence $5%) 
when tolvaptan was administered at a dose ranging from 15 
to 60 mg/day, were thirst, dry mouth, asthenia, constipation, 
polyuria, and hyperglycemia.22
Constipation, diarrhea, esophageal varices, thirst, 
  malaise, pyrexia, increased blood uric acid and glucose, 
anorexia, insomnia, pollakiuria, nausea, vomiting, cough, 
hypo- and hyperkalemia, hypotension, dizziness, chest 
pain, anemia, headache, urinary tract infection, renal failure, 
pneumonia, ventricular tachycardia, atrial fibrillation, pain in 
extremity, and dry skin and mouth were side effects reported 
in   clinical trials.32,33
Tolvaptan in the treatment  
of hyponatremia
Given the aquaretic effect of tolvaptan, initial clinical trials 
assessed its role in the management of hyponatremia. In order 
to compare tolvaptan to fluid restriction for the management 
of euvolemic and hypervolemic hyponatremia, a multicenter, 
prospective, randomized, open-label, active-controlled, 
dose titration trial was conducted.34 Hyponatremic patients 
with serum Na+ concentration ,135 mEq/L for 2 or more 
  consecutive days were eligible (Table 2).
The primary outcome was normalization of serum Na+ 
concentration ($135 mEq/L or $10% increase in serum Na+ 
level from baseline to the last inpatient assessment).International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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After 2-day placebo run-in period, patients were 
  randomized to tolvaptan or fluid restriction with placebo 
in a 2:1 ratio for the duration of their inpatient stay or 
12 days, whichever occurred first. Tolvaptan was started at 
10 mg/day with daily incremental increases to 15, 30, 45, 
and 60 mg/day as needed to achieve a normal serum Na+ 
level. Fluid restriction was started at 1200 mL/day in the 
placebo group, and adjusted by the investigator to achieve 
normal serum Na+ levels. The study treatment was contin-
ued during the outpatient maintenance period if serum Na+ 
level normalized before day 14, otherwise subjects could be 
withdrawn to allow physicians to administer other treatments. 
The tolvaptan dose or the placebo dose with fluid restriction 
was maintained at the same level throughout the maintenance 
period (days 15–28).
A total of 28 patients were enrolled in the study; 17 
were randomized to tolvaptan, and 11 to placebo with 
fluid restriction. Patients were 66 ± 13 and 67 ± 9 years 
of age (mean ± SD) in the tolvaptan and placebo groups, 
  respectively. Women were 41% and 45% in the tolvaptan and 
placebo groups, respectively. HF was the cause of hypona-
tremia in 50%, 14% had cirrhosis, and 36% had SIADH or 
other cause. The mean (± SD) baseline serum Na+ levels were 
129 ± 3 mEq/L (tolvaptan), and 129 ± 4 mEq/L (placebo). In 
the tolvaptan group, 2 out of the 17 patients were withdrawn 
during the run-in period because of protocol violations or 
meeting withdrawal criteria. The remaining 15 patients 
received tolvaptan, but only 12 completed the treatment 
period and received the study drug during the maintenance 
period, the rest had adverse events preventing them from 
completing the study. Only 6 patients completed the 28-day 
outpatient maintenance period, the other 6 patients were 
withdrawn due to adverse events (1 patient), losing follow 
up (1 patient), meeting withdrawal criteria (2 patients), and 
withdrawing consent due to personal reasons (2 patients). 
In the placebo group, 3 out of the 11 patients were withdrawn 
Table 2 Tolvaptan studies in hyponatremic patients
Reference 
Design
Intervention Patient  
population
Major measures Major results
Multicenter,  
prospective,  
randomized,  
open-label,  
active-controlled,  
dose titration34
Patients were 
randomized  
to tolvaptan  
or fluid  
restriction  
with placebo
n = 28  
Hyponatremic  
patients with  
serum Na+  
concentration  
,135 meq/L
Normalization  
of serum Na+  
concentration
A total of 11 patients normalized their Na+ levels 
by the last inpatient visit in the tolvaptan group 
compared to 3 patients in the placebo group 
(P = 0.049)  
50% of the patients achieved normalization in their 
Na+ level within 4 days in the tolvaptan group 
compared to 8 days in the fluid restriction group 
(P , 0.03)  
Tolvaptan patients had significantly larger increases 
in mean serum Na+ from baseline
Two randomized,  
double-blind,  
placebo-controlled,  
Phase III trials35
Patients were 
randomized  
to receive 15 mg/day  
of oral tolvaptan or  
placebo for 30 days
n = 448  
euvolemic or  
hypervolemic  
hyponatremic  
patients
The change in the  
average daily area  
under the curve (AUC)  
for the serum Na+  
concentration from baseline  
to day 4 and day 30  
The percentage of patients  
with normalized serum  
Na+ concentration  
at day 4 and 30
Tolvaptan significantly increased the average daily 
AUC for the serum Na+ concentration from 
baseline to study day 4 and during the entire  
30-day study period as compared with placebo  
Significantly more patients in the tolvaptan group 
had normal serum Na+ concentration and fewer 
patients had marked hyponatremia at day 4 and 
day 30, as compared with placebo
Open-label  
extension  
of the SALT-1  
and SALT-2 trials36
4-year sequential,  
open-label  
extension of  
the SALT-1  
and SALT-2 trials
n = 111  
euvolemic or  
hypervolemic  
hyponatremic  
patients
evaluate the safety  
and efficacy of  
long-term tolvaptan  
use in hyponatremia
Multiple adverse events were judged to be related 
to tolvaptan
Post hoc analysis  
on the SALT trials37
7 patients were 
randomized  
to receive  
tolvaptan and  
12 to placebo
n = 19  
Schizophrenic 
patients  
with idiopathic  
hyponatremia
evaluate the effects  
of tolvaptan  
on idiopathic  
hyponatremia in  
schizophrenia
Tolvaptan patients had significantly greater 
increase in the average daily AUC for Na+ 
concentration from baseline to day 4, as compared 
with placebo  
Mean serum Na+ concentrations were significantly 
higher at all measurement times after receiving the 
study medication except at 8 hours, where it was 
marginally different (P = 0.07)International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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during the run-in period because of protocol violations 
or meeting withdrawal criteria. The remaining 8 patients 
received placebo and were placed on fluid restriction; 
  however only 2 patients completed the treatment period and 
both of them completed the 28-day outpatient maintenance 
period. The other 6 patients were withdrawn due to adverse 
events (2 patients), insufficient response (1 patient), meeting 
withdrawal criteria (1 patient), and withdrawing consent due 
to lack of effect (2 patients).
The mean ± SD dose of tolvaptan was 26 ± 15 and 
28 ± 18 mg/day during the initiation phase and maintenance 
phase, respectively. The mean ± SD duration of treatment 
with tolvaptan was 7 ± 3.6 and 14 ± 8 days in the initia-
tion phase and maintenance phase, respectively. Tolvaptan 
patients had significantly larger increases in mean serum 
Na+ from baseline, which was observed as early as 4 hours 
after the first dose, reached plateau by day 5, and persisted 
through the last inpatient visit, compared with fluid restric-
tion patients. The mean ± SD change in serum Na+ level was 
4.7 ± 3.1 and −0.3 ± 4 in the tolvaptan and placebo groups, 
respectively (P = 0.039). A total of 11 patients normalized 
their Na+ levels by the last inpatient visit in the tolvaptan group 
compared with 3 patients in the placebo group (P = 0.049). 
Half the patients (50%) achieved normalization in their Na+ 
level within 4 days in the tolvaptan group compared with 
8 days in the fluid restriction group (P , 0.03).
As expected, urine output was significantly higher in 
the tolvaptan group at baseline and at the last inpatient day 
compared with fluid restriction group. No differences in 
serum K+, blood pressure, heart rate, thirst score, or adverse 
effects requiring drug discontinuation were observed between 
the 2 groups.
This study showed that tolvaptan without fluid restriction 
was more effective than fluid restriction alone in normal-
izing hyponatremia. However it is limited by small sample 
size, the number of subjects who withdrew early, and the 
  short-term follow up.
The SALT-1 and SALT-2 trials (Study of Ascending Levels 
of Tolvaptan in Hyponatremia 1 and 2) are 2 relatively large, 
randomized, double-blind, placebo-controlled, phase III trials 
conducted to evaluate the effect of tolvaptan on euvolemic 
and hypervolemic hyponatremic patients (Table 2).35
Patients with euvolemic or hypervolemic hyponatremia 
(serum Na+ concentration ,135 mEq/L) were included. 
Exclusion criteria included psychogenic polydipsia, head 
trauma, postoperative conditions, uncontrolled hypothyroid-
ism or adrenal insufficiency, any hyponatremic condition 
associated with the use of medications that can be safely 
stopped, or hypovolemic hyponatrmia.
The patients were randomized to receive 15 mg/day 
of oral tolvaptan in the morning or matching placebo for 
30 days. Fluid restriction was not mandatory, but treatment 
with lithium, demeclocycline, or urea was not permitted. The 
tolvaptan dose was adjusted to maintain a serum Na+ con-
centration between 135 and 145 mEq/L, per study protocol. 
Patients were hospitalized the first day of the study and the 
majority were discharged by day 4.
Patients’ evaluation was conducted at baseline, 8 hours 
after drug administration, and in days 2, 3, 4, 11, 18, 25, 30, 
and 37. The study medication was stopped at 30 days, and 
the effect of discontinuation was studied on the last evalu-
ation (day 37). The 2 primary end points of the study were: 
the change in the average daily AUC for the serum Na+ 
concentration from baseline to day 4 and day 30.   Secondary 
outcomes included the change in the AUC for serum Na+ 
concentration in patients with marked hyponatremia, the 
absolute serum Na+ concentration at each visit, the time to 
normalization of serum Na+ concentration, the percentage 
of patients with normalized serum Na+ concentration at 
day 4 and 30, the categorical serum Na+ concentration at 
day 4 and 30   (normal, .135 mEq/L; mild hyponatremia, 
130–135 mEq/L; or marked hyponatremia, ,130 mEq/L), 
fluid intake and output at day 1, change in body weight in 
hypervolemic patients at day 1, fluid restriction or use of 
rescue intravenous saline, and the change in scores on the 
physical component summary and mental component sum-
mary of the medical outcomes study 12-item short-form 
(SF-12) general health survey.
In the SALT-1 trial, 205 patients were randomized; 
102 patients received tolvaptan, and 103 patients received 
placebo. The percentage of patients who completed the trial 
(30-day study period and 7-day follow up) was 77.5% in 
the tolvaptan group and 63.1% in the placebo group. Mean 
(±SD) age was 60 ± 14 and 60 ± 13 in the tolvaptan and 
placebo groups, respectively. Females were 49% and 40% 
in the tolvaptan and placebo groups, respectively. In the 
SALT-2 trial, 243 patients were randomized; 123 patients 
received tolvaptan, and 120 patients received placebo. The 
percentage of patients who completed the trial was 74.8% in 
the tolvaptan group and 74.2% in the placebo group. Mean 
(±SD) age was 62 ± 15 and 63 ± 14 in the tolvaptan and 
placebo groups, respectively. Females were 39% in both 
tolvaptan and placebo groups. The patients’ demographic 
and baseline characteristics were similar in the study groups 
of both trials.
Tolvaptan significantly increased the average daily AUC 
for the serum Na+ concentration from baseline to study 
day 4 and during the entire 30-day study period compared International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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with placebo. Tolvaptan significantly increased serum Na+ 
concentration within 8 hours of administration compared 
with placebo, in both trials. This statistical superiority was 
maintained at all subsequent visits. With tolvaptan, the serum 
Na+ concentration approached the normal range more rapidly, 
compared with placebo in both trials. At day-37, after dis-
continuation of the study medication, there was no statistical 
difference in serum Na+ concentration in both SALT-1 and 
SALT-2 trials.
In both trials, significantly more patients in the tolvaptan 
group had normal serum Na+ concentration and fewer patients 
had marked hyponatremia at day 4 and day 30, compared 
with placebo. On day-30, scores on the physical component 
summary of the SF-12 health survey did not differ signifi-
cantly between the groups in both trials. However, the mental 
component summary improved in the tolvaptan group in 
the combined analysis of both trials (P = 0.02), in SALT-1 
(P = 0.04), and in the combined subgroup of marked hypona-
tremia (P = 0.04), but not in SALT-2 (P = 0.14).
In both trials, the following side effects were observed 
in the tolvaptan group: dehydration with hypotension, dehy-
dration with dizziness, syncope, acute renal failure, ascites, 
increased serum Na+ and creatinine concentrations, and 
E. coli sepsis with respiratory failure. In the tolvaptan group, 
eight patients were withdrawn from the study due to adverse 
events that were potentially related to the study treatment; 
rash, dysgeusia, nocturia, urinary frequency, exanthema, 
muscle weakness, and hypernatremia. The number of deaths 
in the 2 groups within the defined observation period was 
similar. In the tolvaptan group, only 4 patients exceeded the 
desirable rate of Na+ correction during the first 24 hours 
(.0.5 mEq/L/hour), and the maximum observed rate was 
0.61 mEq/L/hour. In the tolvaptan group, 1.8% of the patients 
had a serum Na+ concentration .146 mEq/L.32
The 2 trials unequivocally proved that tolvaptan, when 
added to standard therapy, was superior to placebo in rais-
ing and maintaining serum Na+ concentration in patients 
with euvolemic and hypervolemic hyponatremia of diverse 
etiologies. They also showed that the benefit was confined to 
its continuous usage without long lasting effect.
The SALTWATER trial (Safety and sodium Assessment 
of Long-term Tolvaptan With hyponatremia: A   year-long, 
open-label Trial to gain Experience under Real world 
  conditions) was a 4-year sequential, open-label exten-
sion of the SALT-1 and SALT-2 trials (Table 2).36 It was 
conducted to evaluate the safety and efficacy of long-term 
tolvaptan use in   hyponatremia. Out of the 325 patients 
who completed the SALT-1 and SALT-2 trials, 111 were 
enrolled (38 patients from SALT-1, and 73 from SALT-2). 
In this study, 49.5% of the patients were men, and the mean 
(±SD) age of patients was 64.6 ± 15.0. The median time from 
completion of SALT-1 and SALT-2 trials to enrollment in 
the   SALTWATER was 30 days per patients. A total of 64 
of the enrolled patients discontinued treatment during the 
follow up period for a variety of reasons. Mild hyponatremia 
was seen in 46.8% of the patients (serum Na+ concentration 
between 130–134 mEq/L), and the rest had marked hypona-
tremia (serum Na+ concentration , 130 mEq/L) at baseline 
in SALT-1 and SALT-2. Upon enrollment in SALTWATER, 
15.3% of the patients had normal serum Na+ concentration, 
53.2% had mild hyponatremia, and 31.5% had marked 
hyponatremia. HF was the etiology of hyponatremia in 
29.7% of the patients, while cirrhosis accounted for 18.0%, 
and SIADH and other causes were 52.3%. The mean dose 
of tolvaptan was increased to 30 mg/day during the first 16 
to 20 weeks, and maintained at that level for the rest of the 
study period.
The patients were followed while they were on tolvaptan 
therapy for a mean of 701 days. During that time, 105 patients 
had adverse effects. Pollakiuria, thirst, fatigue, dry mouth, 
polydipsia, polyuria, hypotension, hypernatremia, dizziness, 
headache, peripheral edema, and acute renal failure were 
the most common adverse effects that were judged to be 
tolvaptan-related.
A total of 64 patients were withdrawn from the study. 
Adverse effects were the reason for withdrawal in 19 patients 
from which 6 patients died (cardiac failure, esophageal 
varices, hepatic cirrhosis, cerebral hemorrhage, and gastro-
intestinal hemorrhage). The adverse effects in the surviving 
13 patients were ventricular tachycardia, vertigo, gastroin-
testinal hemorrhage, vomiting, gait disturbance,   irritability, 
increase in serum creatinine or Na+, anorexia, bladder 
  cancer, dysphasia, myocardial infarction, psychotic disorder, 
renal failure, and pruritus. Out of those, severe ventricular 
  tachycardia, severe irritability, mild increase in serum Na+, 
mild anorexia, severe increase in serum creatinine, and 
moderate pruritus were judged to be possibly or probably 
related to tolvaptan.
An additional 13 patients died as an outcome of an adverse 
effect without being withdrawn from the study   (cardiac 
failure, renal failure, respiratory failure, cardiac arrest, 
  cardiorespiratory arrest, hepatorenal syndrome,   pneumonia, 
cerebral hemorrhage, sepsis, and urosepsis),   giving a total 
of 19 deaths. Out of the 19 patients who died, only the death 
of the patient with the severe hepatorenal syndrome was 
judged to be possibly related to tolvaptan. Five patients International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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had .1 mEq/L/hour increase in serum Na+   concentration 
within the first 8 hours, and 18 patients had serum Na+ 
concentration .145 mEq/L at individual time points (1 was 
withdrawn from the study, while the   hypernatremia resolved 
in the other 17 patients).
Serum Na+ concentration at baseline ranged between 114 
and 141 mEq/L with a mean (±SD) of 130.8 ± 4.4 mEq/L. 
Correction of serum Na+ levels occurred at similar rates dur-
ing the first 8 hours in SALTWATER and the SALT-1 and 
SALT-2, and by day 14, serum Na+ levels reached similar 
plateau. After the initial titration period, mean serum Na+ lev-
els remained normal throughout the study period (.4 years). 
The rate of serum Na+ correction was greater at the begin-
ning in the subgroup of patients with marked hyponatremia, 
but similar kinetics were observed in the mild and marked 
hyponatremia groups, and in the HF and SIADH/other cause 
groups. Patients with cirrhosis had a trend of lower final 
serum Na+ levels. More than 60% of the marked hypona-
tremia group and 45% of the mild hyponatremia group had 
normal Na+ level by week 4. Similar serum Na+ level correc-
tion rates were observed in the HF and SIADH/other cause 
groups, whereas cirrhosis patients had lower rates.
Serum Na+ levels declined in all patient subgroups by day 
7 of withholding tolvaptan. The percentage of the patients 
who had $3 mEq/L drop in their Na+ level with tolvaptan 
discontinuation was 68%, and a similar proportion of patients 
dropped to ,135 mEq/L. In the mild and marked hypona-
tremia subgroups, 122.3 ± 184.3 and 162.5 ± 186 days were 
the mean (±SD) time for first fluid restriction, respectively. 
Fluid restriction was required in 13.2% and 5.4% of patients 
in the mild and marked hyponatremia subgroups, respective-
ly.33 The study proved that the effect of tolvaptan on increas-
ing serum Na+ concentration was maintained long term, and 
although there were numerous adverse events the trial did not 
have a comparator group of an equally ill cohort treated with 
placebo over this long period of time.
Josiassen et al conducted a post hoc analysis on the 
SALT trials to evaluate the effects of tolvaptan on idiopathic 
hyponatremia in schizophrenia (Table 2).37 A total of 24 sub-
jects in the SALT trials had schizophrenia or schizoaffective 
disorder, and 19 of them had idiopathic hyponatremia. The 
other 5 patients had HF (2 patients) or liver cirrhosis (3 
patients) as a cause for their hyponatremia; hence they were 
excluded from this analysis. Out of the 19 subjects, 7 were 
randomized to receive tolvaptan and 12 to placebo. Mean age 
(±SD) was 52.3 ± 10.4 and 49.6 ± 10 years in the tolvaptan 
and placebo groups, respectively. Males were 57.1% and 
91.7% in the tolvaptan and placebo groups, respectively. The 
baseline characteristics of the 2 groups were similar except 
for the dose of antipsychotic medications which was higher 
in the tolvaptan group.
Tolvaptan patients had significantly greater increase in 
the average daily AUC for Na+ concentration from base-
line to day 4, compared with placebo (mean ± SD were 
5.14 ± 3.14 vs 0.91 ± 2.6 mEq/L, respectively, P = 0.0055). 
The same was also observed from baseline to day 30; 
7.51 ± 2.75 mEq/L (mean ± SD) in the tolvaptan group 
compared with 1.39 ± 1.9 mEq/L (mean ± SD) in the placebo 
group (P , 0.001). Mean serum Na+ concentrations were 
significantly higher at all measurement times after receiving 
the study medication except at 8 hours, where it was margin-
ally different (P = 0.07). Subjects on higher doses of antip-
sychotic drugs showed greater improvement in their serum 
Na+ concentration. Only 1 subject (on placebo) required fluid 
restriction, and no subject required rescue therapy or had 
excessive increase in serum Na+ concentration.
No significant changes in serum creatinine or K+ con-
centrations were noticed. In the tolvaptan group, 2 patients 
experienced dehydration and hypotension; 1 was judged to 
be unrelated to tolvaptan, and the other was transient and due 
to patient misunderstanding of fluid restriction. No long-term 
adverse effects were observed, and moreover, no adverse 
symptoms were noticed after drug discontinuation.
This study showed the feasibility of using tolvaptan 
as a treatment of hyponatremia in this special population. 
However, this is a post hoc analysis of the SALT trials, 
and it would be desirable to target this population in future 
prospective trials.
Use of tolvaptan in heart failure
The SALT trials were 2 of the major trials conducted to evalu-
ate the effects of tolvaptan in hyponatremic patients.35 In both 
trials, HF was a major etiology for hyponatremia, accounting 
for 33% in the SALT-1, and 29% in the SALT-2.35
Several randomized, double-blind studies were con-
ducted in patients with HF to assess the effect of tolvaptan 
on   congestion, hemodynamics, left ventricular remodeling, 
HF hospitalization, and survival.
A multicenter, randomized, double-blind, placebo-
  controlled trial was conducted to evaluate the effects of 
chronic tolvaptan use on congestion in patient with HF irre-
spective of their ejection fraction. Patients had to have HF 
symptoms for at least 30 days, and signs of volume overload at 
screening despite diuretic use for at least 30 days, with a fixed 
dose (40–240 mg) of furosemide for at least 7 days before 
  enrollment. All patients received standard HF treatment.38International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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The primary outcome of the study was the change in 
body weight on day 14 from baseline. Secondary outcomes 
included ankle edema, urine Na+ excretion, urine volume, and 
urine osmolality. Patients had 3-day run-in period (random 
assignment period) during which they were stratified for base-
line furosemide dose (40–79 mg or 80–240 mg) and a sepa-
rate random assignment was done in each stratum to maintain 
an overall balance between the different tolvaptan groups. 
After that period, they entered a 25-day treatment period in 
an outpatient setting. A total of 254 patients were enrolled 
in the study; 64, 64, 63, and 63 patients were randomized to 
30, 45, or 60 mg tolvaptan, or placebo, respectively. Mean 
(±SD) ages were 67.6 ± 10.9, 65.6 ± 13.1, 68.5 ± 13.6, and 
65.1 ± 12.9 in the 30, 45, and 60 mg tolvaptan, and placebo, 
respectively. Men were 62.5, 60.9, 60.3, and 73.0% in the 
30, 45, and 60 mg tolvaptan, and placebo, respectively. The 
percentage of patients completing the study was 87%.
The patients were to return to the clinic on day 3, 4, 7, 10, 
14, 21, and 28 during the treatment period. A dose-dependent, 
statistically significant, decrease in body weight from base-
line was observed on the first day of tolvaptan treatment at 
all doses and maintained throughout the study, as compared 
with placebo. The decrease in body weight was similar in 
all tolvaptan patients irrespective of left ventricular ejection 
fraction. Urine volumes were 3909, 4232, 4597, and 2328 mL 
in the 30, 45, and 60 mg tolvaptan, and placebo, respectively 
(P , 0.05, compared with placebo). Despite the increase in 
fluid intake with tolvaptan therapy, the mean net fluid losses 
were significantly higher as compared with   placebo; 1337, 
988, 1286, and 98 mL in the 30, 45, and 60 mg tolvaptan, 
and placebo, respectively (P , 0.05 at each dose). Urine 
osmolality decreased to a mean ± SD of 15.47 ± 189.95, 
52.34 ± 164.69, and 118.77 ± 131.66 mOsm/kg in the 30, 
45, and 60 mg tolvaptan groups, respectively, while an 
increase of 135.81 ± 189 mOsm/kg was observed with 
placebo (P , 0.05). Tolvaptan was also associated with 
significantly higher total urinary Na+ excretion and lower 
urine Na+ concentrations compared with placebo (P , 0.05 
for both).
Small mean increases (,4 mEq/L) in serum Na+ con-
centrations were observed with tolvaptan compared with 
small mean decreases (,1 mEq/L) with placebo. Serum Na+ 
concentrations remained within the normal limits in most 
of the tolvaptan-treated patients. Above normal increases in 
serum Na+ concentration were seen in 6, 11, 13, and 5% of 
the patients on 30, 45, and 60 mg tolvaptan, and placebo, 
respectively, but did not require correction. The observed 
changes in serum Na+ concentrations were significantly 
different between tolvaptan groups and placebo group at all 
times except for the 45 mg group at day 25. Hyponatremia 
was seen in 28% of the patients in this study (serum Na+ 
concentration ,136 mEq/L), and those patients showed 
greater increases in serum Na+ that remained within the 
normal range during the study (normalization was seen on 
day 1 in 80% of tolvaptan group vs 40% in placebo group, 
P , 0.05). However, normonatremic patients had an acute 
and transient increase in Na+ levels, with values returning to 
baseline within 3 weeks of therapy. Normalization of serum 
Na+ concentrations was maintained in 82% of tolvaptan 
group vs 40% of placebo group at the last treatment day 
(P , 0.05).
Statistically significant improvement in ankle edema 
was observed at all times with 45 mg of tolvaptan compared 
with placebo (P , 0.05). No significant differences in the 
quality of life, heart rate, diastolic blood pressure, systolic 
blood pressure, serum K+ concentrations, or renal function 
were observed between the placebo and tolvaptan groups. 
Dry mouth, thirst, polyuria, and urinary frequency were 
higher with tolvaptan.
This study suggests that tolvaptan decreases body weight, 
normalizes serum Na+ concentration in patients with hypona-
tremia, and ameliorates edema in patients with chronic HF 
with mild signs of congestion on chronic diuretic therapy. 
However, this study was limited to patients with mild signs 
of congestion, and the results do not necessarily apply to all 
patients with HF.38
The Acute and Chronic Therapeutic Impact of a 
  Vasopressin Antagonist in Congestive Heart Failure (ACTIV 
in CHF) is a multicenter, randomized, double-blind, placebo-
controlled, parallel-group, dose-ranging, phase 2 feasibility 
trial that was conducted to evaluate the short-term and 
intermediate-term effects of tolvaptan in patients hospital-
ized with HF.39,40 Patients were included in the study if they 
were admitted for worsening HF, had left ventricular ejection 
fraction , 40% within 1 year of admission, and systemic 
congestion (jugular venous distention, rales, or peripheral 
edema) after initial in-hospital therapy for HF.
Patients were screened within 72 hours and random-
ized within 96 hours of admission if they continued to have 
signs and symptoms of congestion despite standard therapy 
(including diuretics) and were randomized in a 1:1:1:1 ratio 
to tolvaptan 30, 60, or 90 mg/day or placebo. The study had 
an inpatient period (up to 10 days), and an outpatient period 
(7 weeks). Study drug was given daily at 9 am during the 
inpatient and outpatient periods. Patients were withdrawn 
from the study if they were hospitalized for .10 days after International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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first dose. During the outpatient period, patients were seen 
in the office on weeks 1, 3, 5, and 7, and a safety phone call 
was conducted 30 days after last dose administration.
The study had 2 primary end points: change in body 
weight at 24 hours, and worsening HF at 60 days (hospi-
talization for HF, unscheduled emergency department or 
office visit for HF requiring increased or new therapy, or 
death). Secondary end points included changes in dyspnea, 
jugular venous distention, rales, edema, body weight, urine 
output, serum electrolyte levels, length of hospital stay after 
randomization, diuretics use, and patient- and physician-
assessed symptoms scale.
A total of 319 patients were randomized; 78 patients 
were assigned to 30 mg tolvaptan, 84 patients to 60 mg 
tolvaptan, 77 patients to 90 mg tolvaptan, and 80 patients to 
placebo. Mean (± SD) age was 62 ± 14, 62 ± 13, 62 ± 14, 
and 60 ± 14 years in the 30, 60, and 90 mg tolvaptan and 
placebo groups, respectively. Men were 68%, 59.5%, 79.2%, 
and 75.0% in the 30, 60, and 90 mg tolvaptan and placebo 
groups, respectively (P = 0.04). There were no other differ-
ences between the groups except for history of percutane-
ous coronary intervention/coronary artery bypass graft 
(P = 0.02).
On the first day of treatment, dose-independent and sig-
nificantly higher decreases in body weight were observed 
with tolvaptan treatment. The median (interquartile 
range)   reductions were −1.80 (−3.85 to −0.50), −2.10 
(−3.10 to −0.85), −2.05 (−2.80 to −0.60), and −0.60 (−1.60 to 
0.00) kg for tolvaptan 30, 60, and 90 mg, and placebo groups, 
respectively; P = 0.02, 0.02, and 0.009 for the three tolvaptan 
groups compared with placebo. The median (interquartile 
range) reductions in body weight from baseline to discharge 
were −3.30 (−7.30 to −1.35), −2.80 (−5.90 to −1.80), −3.20 
(−5.80 to −1.60), and −1.90 (−4.20 to −0.50) kg for tolvap-
tan 30, 60, and 90 mg, and placebo groups, respectively; 
P = 0.006, 0.02, and 0.06 for the 3 tolvaptan groups compared 
with placebo.
The mean ± SD of the first day urine output was signifi-
cantly higher in all tolvaptan groups compared with placebo; 
4056.2 ± 2310.2, 4175.2 ± 2695.4, 4127.3 ± 2050.8, and 
2296.5 ± 1134.1 mL for the tolvaptan 30, 60, and 90 mg, 
and placebo, respectively (P = 0.02, ,0.001, and ,0.001 for 
the three tolvaptan groups as compared with placebo). This 
difference was maintained throughout the hospitalization 
period. Fewer tolvaptan patients had dyspnea, jugular venous 
  distention, and peripheral edema on discharge as compared 
with placebo, but the difference was statistically significant 
only with dyspnea (P = 0.04). No significant   improvement in 
the assessment scales were observed between the tolvaptan 
and placebo groups, and the median time between random-
ization and discharge was the same (4 days). There was no 
significant difference in worsening HF between the 2 groups 
during the outpatient period of the study. Diuretic use 
decreased in both groups after discharge, but the difference 
in the reduction was not statistically significant.
One day after randomization, serum Na+ level increased by 
a mean ± SD of 2.77 ± 3.56, 3.38 ± 4.84, and 3.5 ± 3.63 mEq/L 
in the tolvaptan 30, 60, and 90 mg groups, compared 
with a decrease in sodium concentration with placebo 
(−0.20 ± 3.12 mEq/L). Hyponatremia was seen in 21.3% 
of the patients (serum Na+ concentration ,136 mEq/L) at 
randomization, and they showed rapid increase and often nor-
malization in their Na+ levels that was maintained throughout 
the study. In post hoc analysis, total mortality was lower in 
the combined tolvaptan groups (10%) compared with placebo 
(22.5%) in patients with elevated blood urea nitrogen (BUN) 
(.29 mg/dL), but this did not reach a statistical significance 
(P = 0.07). Furthermore, total mortality was lower in the 
combined tolvaptan groups (5.6%) compared with placebo 
(17.8%) in patients with severe systemic congestion (presence 
of dyspnea, jugular venous distentions [JVD], and edema), 
and this was statistically significant (P = 0.03). However, post 
hoc analysis results can only be used as hypothesis generat-
ing results to guide future prospective studies. Tolvaptan 
did not cause any hypotension, tachycardia, worsening renal 
function, or abnormalities in serum K+ level, however, thirst 
was more frequently encountered.
This study indicated that tolvaptan, on top of standard HF 
therapy including diuretics, increased net fluid loss resulting 
in lower body weight compared with standard therapy alone in 
patients hospitalized for HF. Tolvaptan also improved serum 
Na+ levels in patients with hyponatremia.
In order to evaluate the effect of tolvaptan on short term 
symptoms and long term outcome of patients with HF36 the 
Efficacy of Vasopressin antagonism in Heart Failure Outcome 
Study with Tolvaptan (EVEREST) was conducted.41
EVEREST consisted of three studies; 2 identical studies 
designed to investigate the short-term effects of tolvaptan 
on the clinical status and symptoms and an outcome study 
consisting of all randomized patients, designed to investi-
gate long-term clinical outcome. The outcome study had 2 
primary end points: all cause mortality and the composite 
of cardiovascular death and rehospitalization for HF. The 
  secondary outcomes included the composite of cardio-
vascular mortality or cardiovascular rehospitalization, 
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  worsening of HF (death, hospitalization for HF, or unsched-
uled visit for HF), changes in body weight at day 1, serum 
Na+ level at day 7 or discharge in patient with a baseline 
serum Na+ level ,134 mEq/L, edema score at day 7 or 
discharge in those with a baseline edema, patient-assessed 
dyspnea in those with dyspnea at baseline, and Kansas City 
  Cardiomyopathy   Questionnaire (KCCQ) overall summary 
score at outpatient week 1. Tertiary end points included 
change in KCCQ domains at outpatient weeks 1 and 24, and 
at end of treatment.
EVEREST was a prospective, international, multicenter, 
randomized, double-blind, placebo-controlled study.32,41 
Patients hospitalized for HF exacerbation were eligible to 
participate in the study within 48 hours of admission. The 
patients had to have reduced left ventricular ejection frac-
tion (#40%), and signs of volume expansion. Patients with 
supine systolic blood pressure , 90 mmHg, serum creati-
nine level . 3.5 mg/dL, serum K+ level . 5.5 mEq/L, and 
  hemoglobin level , 9 g/dL were excluded.
Patients were randomly assigned to receive 30 mg/day 
of oral tolvaptan or placebo. The study included an inpatient 
treatment period and post-discharge treatment and follow up 
period. Patients received the study drug for a minimum of 
60 days. All patients received standard HF therapy includ-
ing diuretics, digoxin, angiotensin converting enzyme 
inhibitors (ACEI), angiotensin receptor blockers, β-blockers, 
  aldosterone blockers, hydralazine, and/or nitrates.
The study randomized 4133 patients; 2072 received 
tolvaptan and 2061 received placebo. The mean (±SD) age 
was 65.9 ± 11.7 and 65.6 ± 12.0 in the tolvaptan and pla-
cebo groups, respectively. Males were 73.4% and 75.4% of 
the patients in the tolvaptan and placebo arms, respectively. 
A total of 9 patients in the tolvaptan group and 6 patients in 
the placebo group did not receive the study medication, and 
hence were excluded from the safety analysis. During the 
study, 22% of the tolvaptan patients and 21% of the placebo 
patients discontinued the study medication prematurely within 
a median time of 8 months from randomization. Patients were 
followed for a median duration of 9.9 months.32
The first primary end point (all cause mortality) was 
not different; 25.9% vs 26.3% in the tolvaptan vs placebo 
groups (Hazard Ratio 0.98; 95% CI 0.87–1.11; P = 0.68). 
The second primary end point (death from cardiovascu-
lar causes or first hospitalization for HF) was reached in 
42.0% of the patients on tolvaptan compared with 40.2% 
in the placebo group (hazard ratio 1.04; 95% CI 0.95–1.14; 
P = 0.55). The composite of cardiovascular death or car-
diovascular hospitalization, the incidence of cardiovascular 
mortality, and the incidence of clinical worsening of HF 
did not differ between the 2 groups. Improvement in the 
patient-assessed dyspnea score at day 1 was seen in 74.3% 
of tolvaptan patients with dyspnea at baseline compared with 
68.0% in the placebo group (P , 0.001). A mean (±SD) of 
1.76 ± 1.91 kg weight reduction at day 1 was observed in the 
tolvaptan group compared with 0.97 ± 1.84 kg in the placebo 
group (P , 0.001).29 Mean (±SD) serum Na+ concentration 
increased by 5.49 ± 5.77 mEq/L at day 7 or discharge in 
the tolvaptan patients with low Na+ level (,134 mEq/L) 
compared with 1.85 ± 5.10 mEq/L in the placebo group 
(P , 0.001). This increase was observed as early as day 1 
and was maintained through 40 weeks of treatment. Mean 
(±SD) BUN levels increased by 1.94 ± 11.70 mg/dL at 
day 7 or discharge in the tolvaptan group compared with 
3.30 ± 12.16 mg/dL in the placebo group (P , 0.001). This 
difference, favoring tolvaptan, was seen as early as day 1 
and persisted long after discharge. This suggests a role for 
tolvaptan in patients with abnormal kidney function that 
limits the use of other commonly used agents that are known 
to worsen kidney function. Mean (±SD) serum creatinine 
level increased by 0.08 ± 0.31 mg/dL at day 7 or discharge 
in the tolvaptan group compared with 0.03 ± 0.35 mg/dL in 
the placebo group (P , 0.001). This difference was also seen 
at many of the long-term follow up points.32
Improvement in the edema score at day 7 or discharge 
was significantly higher in patients with baseline pedal edema 
receiving tolvaptan compared with placebo (P = 0.003). 
Physician-assessed edema was significantly improved with 
tolvaptan as early as day 1, and maintained through post-
discharge week 4. KCCQ overall summary score was not 
different at outpatient week 1, but statistically significant dif-
ferences favoring tolvaptan were observed at the time of the 
last scheduled on-treatment assessment. The differences were 
in the quality of life domain (P = 0.003), the social limitation 
domain (P = 0.05), and the overall summary score (P = 0.02). 
This suggests a possible role for long-term tolvaptan therapy, 
although caution should be used in interpreting these findings 
given their tertiary nature.32
Adverse events were noticed in 89.0% of patients on 
tolvaptan compared with 86.1% of placebo. The study drug 
was discontinued in 6.5% in the tolvaptan group compared 
with 5.5% in the placebo group due to adverse effects. Thirst 
and dry mouth were the only side effects that were observed 
significantly higher in the tolvaptan group (P , 0.001 for 
each).32
In the EVEREST clinical status trials, the primary end 
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patient-assessed global clinical status and body weight at day 
7 or discharge if earlier. Secondary outcomes were patient-
assessed changes in dyspnea at day 1 for patients with base-
line dyspnea; global clinical status at day 7 or discharge; body 
weight at days 1 and 7 or discharge; and peripheral edema at 
day 7 or discharge in patients with baseline edema.42
Out of the 4133 enrolled patients, 2048 were random-
ized to trial A (1018 received tolvaptan, and 1030 received 
placebo), and 2085 to trial B (1054 received tolvaptan, 
and 1031 received placebo). The percentages of treatment 
discontinuation before day 7 (or discharge) were 2.6% and 
2.4% in trial A and B, respectively. Adverse events accounted 
for the discontinuation of the trial in 13 patients (10 in the 
tolvaptan and 3 in the placebo groups) and 3 patients (2 in 
the tolvaptan and 1 in the placebo groups) in trial A and B, 
respectively. Demographic and baseline characteristics were 
similar between the tolvaptan and placebo groups in both 
  trials. Mean ages ranged from 65.6 to 66.0, and males were 
73% to 76%.42
Tolvaptan groups had significantly greater improvement 
in the rank sum analysis of the composite primary outcome 
compared with the placebo groups; the means ± SD were 
1.06 ± 0.43 vs 0.99 ± 0.44 in trial A, and 1.07 ± 0.42 vs 
0.97 ± 0.43 in trial B, respectively (P , 0.001 in both trials). 
However, no significant differences in the improvement of 
global clinical status at day 7 (or discharge) were observed 
between tolvaptan and placebo in both trials. Weight reduc-
tion was significantly higher on day 1 in the tolvaptan groups 
compared with placebo groups (means ± SD were 1.71 ± 1.81 
vs 0.99 ± 1.83 kg in trial A, and 1.82 ± 2.01 vs 0.95 ± 1.85 kg 
in trial B, respectively; P , 0.001 in both trials). This was also 
observed at day 7 (means ± SD 3.35 ± 3.27 vs 2.73 ± 3.34 kg 
in trial A, and 3.77 ± 3.59 vs 2.79 ± 3.46 kg in trial B, 
  respectively; P , 0.001 in both trials). Significantly higher 
number of patients showed improvement in their patient-
assessed dyspnea score on day 1 in the tolvaptan group 
compared with placebo group in both trials. No statistically 
significant difference was noticed in the investigator-assessed 
pedal edema on day 7 between the tolvaptan groups and 
placebo groups. No significant differences in blood pressure 
or heart rate were observed.42
In a combined post hoc analysis of the 2 trials, improve-
ment of dyspnea and rales (over the first 4 days), and orthopnea 
and JVD (during the first 3 days) was higher in the tolvaptan 
groups compared with placebo. Alleviation of fatigue over 
day 3 to 6 was better achieved with tolvaptan compared 
with placebo (P = 0.02 on day 6). In patients with hypona-
tremia at baseline (serum Na+ concentration ,134 mEq/L), 
significantly greater correction of serum Na+ concentration 
was observed with tolvaptan on day 1 and discharge. Serum 
K+, magnesium, osmolality, and creatinine were higher in the 
tolvaptan group, while BUN was lower. Tolvaptan patients 
had a mean reduction of furosemide dose from baseline 
greater than placebo, −55.8 and −42.9 mg/day, respectively 
(P = 0.002). An overall in-hospital mortality was 2.4% and 
2.9% in the tolvaptan and placebo groups, respectively.42
A post hoc analysis was performed on the EVEREST 
database to specifically address the effects of tolvaptan on 
dyspnea relief.43 A 7-point Likert scale was used to measure 
patient-assessed dyspnea anytime on the first calendar day 
(day 1) following the first dose of study therapy. The timing 
of the patient-assessed dyspnea in relation to the first dose of 
study medication varied by patient (few hours post-dose to over 
24 hours), and since patients were randomized within 48 hours 
from admission, the assessment was performed within 1 day to 
over 3 days from admission. During this time, background ther-
apy aimed at relieving signs and symptoms is ongoing, which 
could have underestimated the significance of the results. 
Subgroup analysis was performed on pre-specified groups 
based on demographics (age, sex, and race),   co-morbidities 
(ischemic and non-ischemic HF), baseline status (severity of 
edema, jugular venous distention, dyspnea, ejection fraction, 
and blood pressure), chemistry (BUN, serum creatinine, B-type 
natriuretic peptide, and serum Na+), and in-hospital median 
daily furosemide dose prior to randomization.
Out of the 4133 patients in the EVEREST trial, 3664 had 
baseline dyspnea and were evaluated using the patient-
assessed dyspnea measurement. The patients were distrib-
uted between the 2 groups; 1825 patients received tolvaptan 
and 1829 received placebo. Tolvaptan was associated with 
improvement in patient-assessed dyspnea compared with 
placebo (74.3% vs 68.0%, P , 0.0001). Dyspnea improved 
regardless of its severity at baseline, but the greatest improve-
ment was seen in subjects with continuous dyspnea at 
baseline (75.95% and 65.65% in the tolvaptan and placebo 
groups, respectively, P = 0.0021). Dyspnea improvement 
with tolvaptan was modest within the first 12 hours of first 
dose administration, and persisted for 20 hours, but the mag-
nitude of benefit diminished with time. Tolvaptan effects on 
patient-assessed dyspnea at day 1 were consistent in all of 
the pre-specified subgroups.
This study concluded that tolvaptan’s effects on dyspnea 
relief were greatest within 12 hours after the first dose and 
emphasized the need for early randomization.
In order to assess the hemodynamic effects of tolvaptan 
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functional class III or IV, the EffeCt of toLvaptan on 
  hemodynamIc Parameters in Subjects with hEart failure 
(ECLIPSE) was conducted. It is a randomized, placebo 
controlled study, that enrolled patients with HF for at least 
3 months with an ejection fraction ,40%, on standard HF 
therapy for at least 1 month. Patients with systolic blood 
pressure ,90 mmHg, or serum creatinine $3 mg/dL were 
excluded.44
Before randomization, patients entered a baseline inpa-
tient phase, during which they received their daily dose of 
concomitant background medications, and then 2 hours 
later, a pulmonary artery catheter was inserted. Afterwards, 
patients entered into 2 to 20-hour stabilization period, after 
which the pulmonary capillary wedge pressure (PCWP) 
was measured. Patients were eligible for randomization if 
their PCWP was .18 mmHg on 2 successive readings at 
least 10 minutes apart and were randomized within 2 hours 
to receive tolvaptan 15, 30, or 60 mg, or placebo in 1:1:1:1 
ratio. Those patients have advanced symptomatic HF with 
abnormal baseline hemodynamics, so generalizability of 
these data to all patients with HF is not certain. Hemodynamic 
and renal parameters were assessed at multiple points over 
an 8-hour assessment period during which the background 
diuretics and HF medications were stopped and fluid intake 
was restricted to 250 mL every 2 hours.
The primary efficacy end point was the peak change in 
PCWP from baseline within 3 to 8 hours after drug admin-
istration. Secondary efficacy end points included AUC for 
the change from baseline in PCWP and other hemodynamic 
parameters over the 8-hour evaluation period and renal 
and electrolyte parameters. A total of 181 patients were 
randomized; 44, 43, 46, and 48 patients received tolvap-
tan 15, 30, or 60 mg, or placebo, respectively. The mean 
(±SD) ages were 60.3 ± 11.7, 59.7 ± 13.4, 61.0 ± 11.9, and 
58.9 ± 14.0 in the tolvaptan 15, 30, and 60 mg, and placebo 
groups, respectively. Males were 72.7%, 83.7%, 78.3%, 
and 83.3% in the tolvaptan 15, 30, and 60 mg, and placebo 
groups, respectively.
Tolvaptan showed a statistically significant decrease 
in peak change in PCWP from 3 to 8 hours after drug 
administration as compared with placebo; the means ± SD 
were −6.38 ± 4.12 (P = 0.003), 15.67 ± 4.58 (P = 0.044), 
−5.71 ± 4.35 (P = 0.033), and −4.16 ± 4.57, in the tolvaptan 
15, 30, and 60 mg, and placebo, respectively. The AUC for 
the change from baseline in PCWP over the 8-hour evalua-
tion period was showing a statistically significant difference 
with only the 15 mg tolvaptan compared with placebo. All 
tolvaptan doses produced statistically significantly greater 
changes in peak change in pulmonary artery pressure as 
compared with placebo, but only the 15 and 30 mg doses 
resulted in statistically significant reductions in peak change 
in right atrial pressure. This reduction in right atrial pressure 
is related to volume loss from the increased urine output, 
which can explain the improvement in dyspnea at day 1 after 
tolvaptan administration that was noticed in the EVEREST 
trial. No significant changes in cardiac index, pulmonary 
vascular resistance, and systemic vascular resistance were 
observed.41
A dose-dependent increase in urine output was observed 
with tolvaptan (P , 0.0001 for all tolvaptan groups vs 
  placebo), and urine osmolality was significantly lower with 
all tolvaptan doses as compared with placebo (P , 0.0001). 
Significantly higher free water clearance was observed with 
all tolvaptan doses. Plasma osmolality showed significantly 
small increase with all tolvaptan doses. A dose-related modest 
increase in serum Na+ concentration (mean ± SD) was observed 
with tolvaptan 15 (1.2 ± 2.5 mEq/L), 30 (3.3 ± 3.9 mEq/L), 
and 60 mg (4.6 ± 4.9 mEq/L), as compared with placebo 
group (−0.7 ± 3.2 mEq/L). No significant changes in 
serum   creatinine, BUN, K+, and vital signs were observed. 
  Tolvaptan therapy was well tolerated during this study, and 
there were no drug-related deaths.41
This study showed that tolvaptan administration was 
associated with modest favorable changes in hemodynamics 
in patients with advanced HF.44
The potential beneficial effect of tolvaptan on remodel-
ing was assessed in the Multicenter Evaluation of Tolvaptan 
Effect on Remodeling (METEOR) study, which was a 
multicenter, randomized, double-blind, placebo-controlled 
study. It evaluated the effects of long-term administration 
of 30 mg/day of tolvaptan on left ventricular end-diastolic 
volume (LVEDV) in patients with HF and reduced systolic 
function. LVEDV was assessed by quantitative radionuclide 
ventriculography at baseline, after 1 year of therapy, and 
7 days after study drug withdrawal.45
Patients included in the study were NYHA functional 
class II to III HF, with an ejection fraction #30% within 
1 year from randomization, on standard HF therapy for at 
least 3 months, and with a stable dose for 2 weeks prior to 
enrollment.
A total of 240 patients were enrolled. The patients were 
randomized to receive tolvaptan (120), or placebo (120). 
Mean (± SD) age was 65 ± 12 and 63 ± 12 years in the 
tolvaptan and placebo groups, respectively. Men were 82% 
and 81% in tolvaptan and placebo groups respectively. 
Out of the 120 patients in each group, 91 and 89 patients International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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completed the study in the tolvaptan and placebo groups, 
respectively. At baseline, LVEDV index, left ventricular end 
systolic volume (LVESV) index, and left ventricular ejec-
tion fraction were similar between the tolvaptan and placebo 
groups. At 1 year, the mean (±SD) changes in LVEDV index 
were −1.78 ± 10.7 and 0.04 ± 10.0 mL/m2, in the tolvaptan 
and placebo groups, respectively (P = 0.21). There was also 
no difference in LVED index between the 2 groups 1 week 
after study drug withdrawal.
Changes in LVESV index and left ventricular ejection 
fraction were pre-specified secondary end points in this 
study. None of them was different in tolvaptan group as com-
pared with placebo group at 1 year, and 1 week after study 
drug withdrawal. No difference was seen in blood pressure, 
heart rate, serum Na+, K+, BUN, and creatinine between 
the 2 groups. No statistically significant differences in the 
Minnesota Living With Heart Failure Questionnaire score, 
Visual Analog Scale assessment of global status, respiratory 
status, subject-assessed overall treatment effect, and patient-
assessed global status were noticed between the tolvaptan 
and placebo groups.
Other outcomes were looked at, such as mortality and 
neurohormonal effects of tolvaptan, however they were not 
pre-specified. In the tolvaptan group, 5% death rate, and 18% 
HF hospitalization rate were observed, compared with 9% 
and 28% in the placebo group, respectively. In a time-to-event 
analysis, the composite of mortality or HF hospitalization 
favored tolvaptan (P , 0.03). AVP levels increased with 
tolvaptan treatment as compared with placebo. However, 
BNP levels decreased with tolvaptan and placebo, with a 
larger, statistically insignificant, decrease in the tolvaptan 
group. Urinary frequency, thirst, and dry mouth were more 
commonly reported with tolvaptan treatment in this trial.
This trial demonstrated that tolvaptan therapy had no 
significant effect on left ventricular remodeling.42 Although 
the outcome was disappointing as the hope for reversed 
remodeling did not materialize, it alleviated the concern that 
using selective V2 receptor antagonist might have a deleteri-
ous effect from abundant AVP stimulating V1 receptors, that 
could potentially result in vasoconstriction and deleterious 
remodeling.
The effect of tolvaptan on renal hemodynamics, water 
excretion, and neurohormones as compared to diuretic was 
assessed in a randomized, placebo-controlled crossover study, 
in which 14 patients with chronic HF NYHA functional class 
II-III, and left ventricular ejection fraction ,40% within 
1 year prior to enrollment were enrolled.46 Mean (±SD) age 
was 56 ± 8 years, and men were 71%. The patients were 
placed on 2 g/day Na+ diet and ACEI (other than captopril) 
were discontinued and replaced with captopril 15 days before 
the start of the study. Patients were admitted 3 days prior to 
the study and captopril, diuretics, β-blockers, and aspirin 
were discontinued. On day 1, patients received either a single 
dose of placebo or 30 mg tolvaptan and were crossed over to 
furosemide on day 3. On day 5, all patients received 80 mg 
of furosemide. Day 2 and 4 were washout days.
Significant increases in the urine flow were noticed with 
tolvaptan and furosemide compared with placebo (P , 0.05), 
but there was no difference between the 2 medications. 
Urinary Na+ excretion, Na+ clearance, K+ excretion, and K+ 
clearance were significantly higher with furosemide com-
pared with placebo (P , 0.05) and tolvaptan (P , 0.05), 
and there was no difference between the latter 2. Urine 
osmolality decreased with tolvaptan as compared with 
placebo (P , 0.05), and tended to be lower compared with 
furosemide (P = 0.10). Renal blood flow and distal fractional 
reabsorption of Na+ were significantly lower with furosemide 
compared with placebo (P , 0.05) and tolvaptan (P , 0.05), 
with no difference between the latter 2 (P = 0.19). Effective 
renal plasma flow tended to be lower with furosemide com-
pared with placebo and tolvaptan (P = 0.053). There were no 
differences between the 3 groups in mean arterial pressure, 
heart rate, glomerular filtration rate, renal vascular resistance, 
and proximal fractional reabsorption of Na+.
No significant changes in plasma Na+ levels were seen 
with tolvaptan and a trend for a decrease was noted with 
furosemide. No significant differences in serum K+ concentra-
tion were noticed between the groups. Statistically significant 
increases in plasma renin activity and norepinephrine were 
seen with furosemide compared with placebo.
This study demonstrates that tolvaptan enhanced aquare-
sis in HF without adversely affecting hemodynamics, urinary 
Na+ or K+ excretion, serum electrolytes, or neurohumoral 
activation.
Conclusion
Based on the preceding review of the clinical experience 
with tolvaptan, its efficacy in correcting hyponatremia in 
patients with euvolemic or hypervolemic hyponatremia 
is clearly established. The available data on the safety of 
tolvaptan should provide health care providers the needed 
comfort for prescribing it although a larger experience is 
still required.
The unique aquaretic property of tolvaptan, as a V2 recep-
tor antagonist, combined with the evidence documenting sus-
tained weight loss in patients with HF and   hypervolemia make International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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it an attractive option for the management of   hypervolemic 
hyponatremia. Theoretically, activation of V1 receptors by 
the abundant AVP may lead to increased systemic vascular 
resistance and hemodynamic deterioration. However, the 
lack of detrimental effect by tolvaptan on remodeling in 
patients with systolic HF and the neutral effect on outcomes 
should alleviate the concern that the use of selective V2 
receptor antagonists in systolic HF may not be advisable. 
The   concern that the use of selective V2 receptor antagonist 
may be   detrimental in HF has been alleviated.
Despite the neutral effect of tolvaptan on outcomes among 
patients with systolic HF the available safety records provide 
a basis for its use to correct moderate to severe hyponatremia 
among outpatients with systolic HF. The decision to prescribe 
tolvaptan in this setting is not based on any evidence of 
improvement in symptoms or outcome but largely dictated 
by the comfort level of health care providers. The notion that 
in patients with systolic HF and volume overload, tolvaptan 
may provide benefit by either replacing or reducing the dose 
of diuretics is not supported by the available data. The lack of 
neurohormonal activation, however, combined with the lack 
of a negative effect on electrolytes support further research 
effort for this indication.
It should be clearly acknowledged that failure of tolvaptan 
to improve outcome among patients hospitalized with dec-
ompensated systolic HF may entirely be explained by failure 
to target hyponatremic patients. Thus, the potential beneficial 
effects of tolvaptan in improving outcomes in patients with 
decompensated HF associated with hyponatremia have not 
been explored yet.
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